PharmTech
CONTINUE TO SITE >

OR WAIT 15 SECS

Cirrus Pharmaceuticals Announces Manufacturing for Clinical Trials

February 26, 2016
Pharmaceutical Technology Editors

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-03-02-2016, Volume 11, Issue 3

Cirrus Pharmaceuticals will launch services for manufacturing cGMP materials for early-phase clinical trials at its Raleigh-Durham, NC facility.

Cirrus Pharmaceuticals, a Kemwell Company, has announced that it is ready to launch services for manufacturing cGMP materials for early-phase clinical trials in a new suite at its Raleigh-Durham, NC site.

The company offers development and manufacturing capabilities for niche dosage forms. The company will manufacture metered dose inhalers (MDI) on its Pamasol pressure filling line in batch sizes up to 25L. One- and two-step filling as well as cold filling for suspension and solution MDIs will be offered.

Other services include dry powder filling in capsules for dry powder inhalers, and manufacture of nasal solutions, suspensions, and powders. Clinical manufacturing of other dosage forms that will be offered from the site are topicals, oral solids, and oral liquids.

Source: Cirrus Pharmaceuticals, a Kemwell Company